Dosage and administration:
Durabolin injection side effectsis prescribed as an adjunct to diet and exercise to lower blood glucose, its administration should be timed to coincide with a meal.
The drug is taken orally before meals (ie preprandialno 2, 3 or 4 times a day).
It is recommended to take the drug for 15 minutes before the main meals.
permitted the drug in the range from 0 to 30 minutes. Patients may meal passes (or more meals) should receive the instruction, respectively, for the passage of (or additional reception) dose.
The dose is adjusted individually for each patient depending on the concentration of glucose in the blood. In addition to monitoring glucose concentrations in blood and / or urine, which carries the patient, it is also necessary that the blood glucose concentration determined by the physician periodically, which will establish a minimum effective dosage for a given patient. Glycosylated hemoglobin concentration is an indicator of a patient’s response to therapy. Periodic monitoring of the glucose concentration is necessary to detect inadequate reduction of glucose concentration in the blood in the first appointment patient repaglinide at the recommended maximum dose (i.e., if the patient “primary resistance”) as well as to detect attenuation hypoglycemic response to the drug after a previously conducted effective therapy (ie, if the patient has “secondary resistance”).
in patients with type 2 diabetes whose diabetes is usually well controlled with diet, during periods of transient loss of glycemic control may be sufficient to conduct a short course of repaglinide treatment.
in the case of simultaneous application with other drugs – see sections “.
Interaction with other drugs
“And” Cautions “. Initial dose The dose determined by the physician depending on the level of glucose in the blood. For patients who have never received other oral hypoglycemic drugs recommended initial single dose before the main meal is 0.5 mg. Dosage adjustment is performed 1 time per week or 1 to 2 times a week (this guided by blood glucose concentration as indicator of response to therapy). If a patient is transferred from another receiving oral hypoglycemic agents for the treatment of drug durabolin injection side effects, the recommended initial dose before each main meal should be 1 mg. The maximum doserecommended maximum single dose before meals is 4 mg. The total maximum daily dose should not exceed 16 mg. Patients who have previously received other oral hypoglycemic agents: Translation of patients with therapy other oral hypoglycemic drugs to repaglinide therapy can be carried out immediately. At the same time, did not reveal the exact relation between the dose of repaglinide and the dose of other hypoglycemic agents. The maximum recommended starting dose for patients who are transferred to repaglinide is 1 mg before each main meal. Combination therapy Repaglinide can be administered in combination with metformin or thiazolidinediones in case of inadequate control of blood glucose levels on monotherapy with metformin, thiazolidinediones or repaglinide. This uses the same initial dose of repaglinide as monotherapy. Thereafter, the dosage of each drug are adjusted according to the achieved blood glucose concentration. Children and adolescents Efficacy and safety of repaglinide treatment of persons under 18 years of age have not been studied. Data not available.
The most common side effects include changes in blood glucose concentration, i.e., hypoglycemia. The frequency of these reactions depends, as when using any type of treatment of diabetes, the individual factors, such as dietary skills dose, exercise and stress.
The following are the side effects observed when using repaglinide and other oral hypoglycemic agents. All side effects are divided into groups according to the development of frequency specific, as commonly (≥1 / 100 to <1/10); uncommon (≥1 / 1,000 to <1/100); rare (≥1 / 10,000 to <1 / 1,000); very rare (<1 / 10,000) and not known (can not be estimated from the available data). Violations of the immune system Very rare: allergic reactions can detect the reaction of generalized hypersensitivity (eg, anaphylactic reaction), or immunological reactions such as vasculitis. Violations the part of metabolism and nutrition often: hypoglycemia is unknown:. hypoglycemic coma, hypoglycemia with unconsciousness As with other hypoglycaemic agents, hypoglycemia can occur when using repaglinide.Hypoglycemia can manifest the following symptoms: feeling of anxiety, dizziness, sweating, tremor, hunger, difficulty to concentrate. These reactions are in most cases are not severe and can eliminate the intake of carbohydrates. Severe reactions may require medical attention, in particular, intravenous administration of dextrose (glucose). The risk of hypoglycemia may increase the interaction of repaglinide with other drugs (see. Section ”
Interaction with other drugs
. “) Violations of the organ of vision Very rare: visual disturbances Changes in blood glucose levels can lead to visual disturbances, especially at the initial stage of therapy hypoglycemic drugs. Usually, however, these changes are transient in nature. Disorders of the digestive system Common: abdominal pain, diarrhea Very rare: vomiting, constipation Not known: Nausea Complaints about violations of the digestive system – stomach pain, diarrhea, nausea, vomiting and constipation were noted in clinical trials. However, the frequency and severity of these symptoms did not differ from the use of other oral drugs that stimulate insulin secretion. Violations of the durabolin injection side effects liver and biliary tract is very rare: liver function disorders In very rare cases, reported severe hepatic dysfunction, but the causal relationship with repaglinide has not been established. very rare:. increased activity of “liver enzymes” In most cases, these increases were mild and were transient in nature, and very few patients discontinued therapy due to increased activity of “liver enzymes.” Violations of the skin and subcutaneous tissue disorders Not known: hypersensitivity can detect hypersensitivity reactions such as redness, itching, rash, and urticaria.
In a clinical study, patients with Type 2 diabetes received weekly repaglinide in doses increasing from 4 to 20 mg four times a day (every meal) for 6 weeks. In addition to the desired decrease in the concentration of glucose in the blood were observed individual adverse reactions do not affect the safety profile.
Due to an increase in caloric intake in this study hypoglycemia was observed, however a relative overdose may manifest as an excessive fall in the concentration of glucose in the blood with symptoms of hypoglycemia development (dizziness, sweating, tremor, headache, etc.). In the case of the appearance of these symptoms durabolin injection side effects should take appropriate measures to increase the concentration of blood glucose (dextrose or ingest foods rich in carbohydrates). When severe hypoglycemia (loss of consciousness, coma) intravenous dextrose.